Real Word European Registry of NTRK Fusions and Other Rare Actionable Fusions (TRacKING)

Launched by CENTRE LEON BERARD · Jun 9, 2021

Keywords

ClinConnect Summary

The TRacKING trial is a study that aims to gather information about how patients with certain rare types of cancer are treated in real life. Specifically, it focuses on patients who have something called "actionable fusions," which are specific changes in their genes that may affect their cancer. By collecting data from patients' medical records and asking them about their quality of life, the researchers hope to improve the understanding and management of these rare cancers. Participants will be followed for at least two years, allowing researchers to see how different treatments work over time.

To join the study, individuals must be at least 18 years old and have a confirmed diagnosis of cancer with a specific rare gene fusion. They should also be willing to provide their medical information and complete questionnaires about their health and well-being. This trial is open to all adults, regardless of gender, and is currently recruiting participants. By taking part, patients can contribute to valuable research that aims to enhance care for others facing similar challenges.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient with histologically-confirmed cancer
• • Patient harboring a rare actionable fusion (see Appendix 1),
• • Availability of clinical and demographic data, information on treatment and clinical outcome.
• • Adult, ≥18 years old,
• • Patient should understand, sign and date the written voluntary informed consent form.
• Exclusion Criteria:
• • -